thrombolyt therapi thrombolyt agent year past decad clinic use agent treatment acut myocardi infarct avail agent use treatment myocardi infarct streptokinas urokinas tissu plasminogen activ anistreplas agent work uniqu fashion common end point therapi dissolut fibrin clot convers plasminogen number measur end point effect agent treatment acut myocardi infarct mortal reperfus patenc ventricular function ventricular volum quantit creatin kinas isoenzym analysi secondari end point bleed stroke recurr ischem event numer clinic studi effect agent desir end point compar studi sever large-scal trial agent regard efficaci newer regimen avail thrombolyt agent new thrombolyt agent activ investig subject intens research next year lack consensu agent superior clear thrombolyt therapi acut myocardi infarct treatment choic 